HOLLISTON, Mass., April 30, 2013 (GLOBE NEWSWIRE) -- An archived webcast is now available of a press conference held earlier today that detailed the first successful transplant of a regenerated trachea in the United States. The press conference was held at Children's Hospital of Illinois, where the surgery took place, and where the recipient of the implant, two-year-old Hannah Genevieve Warren, is currently recovering. The surgery was the world's first successful pediatric regenerated trachea transplant using a synthetic scaffold. This was also the first regenerated trachea transplant surgery using a scaffold manufactured by Harvard Apparatus Regenerative Technology, Inc. (HART), the wholly owned regenerative medicine technology subsidiary of Harvard Bioscience. The implant used in the procedure was grown in one of HART's "InBreath" bioreactors. Additional details about the surgery can be found in the press release " Harvard Apparatus Regenerative Technology's 'InBreath' Scaffold and Bioreactor Used in First U.S. Transplant of a Regenerated Trachea," released earlier today. The archived webcast of the press conference is available at the following link: http://www.childrenshospitalofillinois.org/trachea-surgery/live-feed.html?utm_source=Newsletter&utm_medium=Email&utm_campaign=Trachea+Surgery++External+Communication Further, the following link leads to an NBC news video describing the landmark surgery: http://www.today.com/video/today/51716123#51716123 About Harvard Bioscience Harvard Bioscience, or HBIO, is a global developer, manufacturer and marketer of a broad range of specialized products, primarily apparatus and scientific instruments, used to advance life science research and regenerative medicine. HBIO sells its products to thousands of researchers in over 100 countries primarily through its 850 page catalog (and various other specialty catalogs), its website, through distributors, including GE Healthcare, Thermo Fisher Scientific and VWR, and via our field sales organization. HBIO has sales and manufacturing operations in the United States, the United Kingdom, Germany, Sweden and Spain with additional facilities in France and Canada. For more information, please visit www.harvardbioscience.com. About Harvard Apparatus Regenerative Technology, Inc. Harvard Apparatus Regenerative Technology, Inc., a wholly owned subsidiary of Harvard Bioscience, develops and manufactures devices for use within the emerging field of regenerative medicine. These devices include bioreactors and synthetic scaffolds for growing tissue and organs outside the body; and injectors for stem cell therapy.
Registration Statement of Harvard Apparatus Regenerative Technology, Inc.A registration statement including a prospectus relating to the common stock of Harvard Apparatus Regenerative Technology, Inc. has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy these securities be accepted before the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Forward-Looking Statements Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements include statements relating to, among other things, activities of Harvard Bioscience and the postponed IPO and other activities of Harvard Apparatus Regenerative Technology. These statements involve risks and uncertainties, including among other things, market conditions that may cause results to differ materially from the statements set forth in this press release. The forward-looking statements in this press release speak only as of the date of this press release. Harvard Bioscience expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.
CONTACT: David Green, President firstname.lastname@example.org Tom McNaughton, CFO email@example.com Chane Graziano, CEO firstname.lastname@example.org Tel: 508 893-8999 Fax: 508 892-6135